Product Description
severe asthma treatment (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31861993/)
Mechanisms of Action: IL5 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2016-004459-65 |
2016-004459-65 | P2 |
Active, not recruiting |
Asthma |
2018-02-16 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/16/2024 |
News Article |
Asthma - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 |
|
09/29/2023 |
News Article |
Eosinophilic Esophagitis Drug Market Future Demand, Business Strategies, Industry Growth, Regional Outlook, Challenges and Forecast |
|
11/21/2022 |
News Article |
Severe Asthma Digital Marketing Trends Report 2022 Featuring Sanofi, Regeneron, Genentech, Novartis, GSK, AstraZeneca, Amgen, & Teva |
|
07/07/2022 |
News Article |
Kinaset Therapeutics Appoints Christopher O'Brien, MD, PhD, FCCP, as Chief Medical Officer |